Form 4: Cardiff Oncology Insider Gary Pace Reports Stock Transactions

Gary Pace, an insider at Cardiff Oncology, reported the purchase of 350,115 shares of common stock and 11,500 shares held by a minor child on December 11, 2024.

Summary

• Gary Pace, an insider at Cardiff Oncology, executed two transactions on December 11, 2024.
• The first transaction involved the purchase of 350,115 shares of common stock at a price of $2.60 per share, totaling $1,047,876.
• The second transaction involved the purchase of 11,500 shares of common stock at a price of $2.60 per share, totaling $29,900, held by a minor child.
• These transactions increased Gary Pace's direct holdings to 1,047,876 shares and indirect holdings to 1059376 shares.

Sentiment

Score: 7

Explanation: The insider purchase is a positive signal, suggesting confidence in the company's future, but it's a single transaction and not a company-wide announcement.

Positives

• The insider purchase of shares may indicate confidence in the company's future prospects.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and the size and frequency of these transactions are often compared to industry peers.
• The purchase of 350,115 shares by Gary Pace is a significant transaction, and the market will likely interpret this as a positive signal.

Stakeholder Impact

• The insider purchase may positively impact shareholder confidence.

Key Dates

Keywords

Cardiff Oncology, Insider Trading, Stock Purchase, Common Stock, Gary Pace